Dec, 2022

U.S.A.
News / Corporate
Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio
Both Companies win a year of access to a prestigious life-science incubator in San Francisco, CA and to Astellas expertise to further their research Award helps biotech start-ups accelerate early...
Read More

Oct, 2022

U.S.A.
News / Corporate
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic
Read More
U.S.A.
News / Corporate
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., "Pantherna") today announced that the companies have...
Read More

Sep, 2022

U.S.A.
News / Corporate
Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ --...
Read More
U.S.A.
News / Corporate
Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
Clinical trial evaluated the safety and tolerability of 30 mg dose for the treatment of vasomotor symptoms (VMS) associated with menopause TOKYO, Sept. 4, 2022 /PRNewswire/ -- Astellas Pharma Inc....
Read More